TRaCkLIGHT study for people with moderate to severe Crohn's Disease

Site Image

Study Overview

Patients with moderate to severe Crohn's disease, who have failed prior treatment with the standard anti-TNF therapy will receive the study medication - MDGN-002 - which may help treat the Crohn's disease and relieve its symptoms.

Study Description

The purpose of this research study is to be studying the safety of this drug, including any side effects related to its use and how well the symptoms are tolerated, while also learning if the study drug MDGN-002 might be useful in treating Crohn’s disease and its symptoms. . MDGN-002 is a research therapy that has been tested before in adults using a single dose. MDGN-002 is not yet approved by the United States Food and Drug Administration (FDA). 

How long will you be in this study?

If you agree to take part, the treatment period will last for 84 days and will involve upto 12 study visits. Study visits will last between 1 and 8 hours.  There will be upto 2 study-related telephone calls.
The total duration of being in the study is about 26 weeks. 



Additional Information:

For additional information, please contact the study coordinator Rupa Chowdary at Rupa.chowdary@pennmedicine.upenn.edu or 215-573-5073

  • Study Identifier: 830065

Recruitment Status

Open

Check to see if you pre-qualify for the study.

Have you been diagnosed by a physician with moderate to severe Crohn's disease ?

BACK
Volunteer Sign up

Volunteer Sign-up

Participate in medical studies to develop new diagnostic and clinical treatments and improve current standards of care.

Sign Up Now!

If you need assistance finding a non-cancer study or if you have any questions, please email psom-ocr@pobox.upenn.edu